5. Available data for comparison 3 (COX‐2 vs traditional NSAID).
| Trial | Groups | Pain on VAS | Withdrawals due to adverse events | BASDAI | Patient's global assessment of disease activity | Duration of morning stiffness | CRP | ASAS 20 | ASAS partial remission | BASFI | BASMI | Chest expansion | Schober's test | Pain relief ≥ 50% | Number of any adverse events | Number of serious adverse events | Adverse events per organ system |
| Barkhuizen 2006 | Celecoxib 400 mg vs Naproxen 500 mg | * | + | * | * | * | * | + | * | + | + | + | |||||
| Dougados 2001 | Celecoxib 200 mg vs Ketoprofen 200 mg | + | + | + | + | + | + | + | + | + | + | + | + | ||||
| Sieper 2008 | Celecoxib 400 mg vs Diclofenac 75 mg | + | + | + | + | + | + | + | + | + | + | + | |||||
| van der Heijde 2005 | Etoricoxib 90 mg vs Naproxen 1000 mg | + | + | + | + | + | + | + | + | + | + | + | + |
+ Available data that was used in the meta‐analysis. * Available data that could not be used in the meta‐analysis. Additional information on all included trials can be found in the Characteristics of included studies.